Mason W D, Conklin J D, Hailey F J
School of Pharmacy and Medicine, University of Missouri, Kansas City 64108.
Pharm Res. 1987 Dec;4(6):499-503. doi: 10.1023/a:1016431706453.
Comparative bioavailability studies should be designed and the resulting data evaluated based on estimates of both intersubject and intrasubject variances in the kinetic parameters for the particular drug products(s) being studied. This report presents the results of two comparative bioavailability studies. In the first study, three production lots of macrocrystalline nitrofurantoin capsules (Macrodantin) were compared in 21 subjects, and in the second study, capsules from one production lot were administered to 21 different subjects on three occasions. Both model-independent kinetic parameters for urinary excretion and a one-compartment model with zero-order absorption were used to evaluate both the rate and the extent of bioavailability. Overall the results showed a very low variance between and within production lots and a relatively large intersubject variance in the rate and extent of absorption.
应设计比较生物利用度研究,并根据所研究的特定药品动力学参数的受试者间和受试者内差异估计值来评估所得数据。本报告展示了两项比较生物利用度研究的结果。在第一项研究中,对21名受试者比较了三个生产批次的大结晶型呋喃妥因胶囊(Macrodantin),在第二项研究中,将来自一个生产批次的胶囊分三次给予21名不同的受试者。使用与模型无关的尿排泄动力学参数以及具有零级吸收的单室模型来评估生物利用度的速率和程度。总体而言,结果显示生产批次之间和批次内部的差异非常低,而吸收速率和程度方面受试者间差异相对较大。